AGMB
AgomAb Therapeutics NV
8.70$
+1.5%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 24 | Q3 25 | Q4 25 | Q1 26 | Q2 26 |
|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 84.2% | 80.3% | 78.9% | 80.3% | 88.8% | |
| 83.1% | 78.2% | 56.2% | 78.2% | 76.2% | |
| 83.1% | 78.2% | 75.8% | 78.2% | 86.6% | |
| 1.0% | – | 2.7% | 1.3% | – | |
| 4.2% | 5.2% | 5.6% | 5.2% | 3.0% | |
| 9.7% | 12.1% | 13.1% | 12.1% | 6.9% | |
| 8.9% | 11.3% | 14.8% | 11.3% | 8.8% | |
| 4.4% | 5.7% | 12.1% | 5.7% | 6.9% | |
| 0.1% | 0.1% | 0.2% | 0.1% | 0.1% | |
| 2.9% | 4.6% | 5.0% | 4.6% | 4.1% | |
| 91.1% | 88.7% | 85.2% | 88.7% | 91.2% | |
| -57.8% | -99.2% | -118.2% | -99.2% | -73.1% | |
| 17.6% | 25.7% | 31.7% | 21.9% | 16.9% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.